In the United States Kawasaki disease occurs yearround, with a greater number of cases observed in winter and spring. Reports from Japan, where the most complete epidemiological surveillance data have been collected, show that epidemics occurred in 1979, 1982, and 1985 . Epidemics have also been reported in the United States and other countries.
The epidemiology of Kawasaki disease suggests that a microbial agent is the cause of this disease. The clinical presentation is also highly suggestive of an infectious etiology; rickettsiae, viruses (primarily Epstein-Barr virus and retroviruses), several bacteria (e.g., group A streptococci, other streptococci, and propionibacteria), and candidae have been suggested as etiologic agents. To date, however, an etiologic agent has not been documented. Epidemiological observations suggest that Kawasaki disease may be associated with living near bodies of water or exposure to house dust mites or recently shampooed carpets. Critical data to substantiate these possible associations are lacking. Although an infectious etiology has been suggested, person-to-person transmission has not been documented, even in day-care centers, a common source for outbreaks has not been defined, and cases among siblings are very rare.
This statement discusses the diagnosis of Kawasaki disease and its treatment during the acute phase. Longterm follow-up of patients with cardiac involvement will be addressed in a subsequent publication by this committee.
Diagnosis of Kawasaki Disease
In the absence of a specific diagnostic test for Kawasaki disease, clinical criteria have been established to assist the physician in making the diagnosis.7 Other clinical and laboratory findings observed in patients with this disease are frequently helpful. 
Principal Clinical Findings
Fever and at leastfour ofthefiveprincipal clinicalfeatures should be present to establish the diagnosis of Kawasaki disease. Patients with fever and fewer than four principal features can be diagnosed as having Kawasaki disease when coronary artery disease is detected by two-dimensional echocardiography or coronary angiography.
The fever is generally high and spiking, and persists in the untreated patient for 1-2 weeks or longer. With appropriate treatment the fever usually resolves in a short period of time. Kawasaki disease should be considered in the differential diagnosis of a young child with unexplained fever.
Changes in the extremities are distinctive. Erythema of the palms and soles and/or firm, sometimes painful induration of the hands or feet often occurs in the early phase of the disease. Desquamation of the fingers and toes usually begins 1-3 weeks after onset of fever in the periungual region and may extend to include the palms and soles. Approximately 1-2 months after the onset of fever, deep transverse grooves across the nails (Beau's lines) may appear. A polymorphous exanthema usually appears within 5 days of the onset of fever. The rash may take various forms, including an urticarial exanthema, a maculopapular morbilliform eruption, a scarlatiniform erythroderma, an erythema-multiforme-like rash, or, rarely, a fine micropustular eruption. Bullous eruptions have not been described. The rash is usually extensive with involvement of the trunk and extremities and accentuation in the perineal region.
Bilateral conjunctival injection usually begins shortly after the onset of fever. It typically involves the bulbar conjunctivae much more than the palpebral or tarsal conjunctivae, is not associated with an exudate, and is usually painless.
Changes of the lips and oral cavity include erythema and cracking of the lips, strawberry tongue, and erythema of the orophyaryngeal mucosa. Oral or lingual ulcerations are not seen.
Cervical lymphadenopathy is considered a principal finding when at least one lymph node is more than 1.5 cm in diameter. The lymphadenopathy is generally unilateral and the nodes are usually firm and slightly tender. There may be some overlying erythema but the nodes are nonfluctuant. Among the five principal clinical features, cervical lymphadenopathy is the least common.
Because the principal clinical findings to fulfill the diagnostic criteria are not specific, other diseases with similar clinical features should be excluded ( Table 2 ). Consideration of measles as a possible diagnosis is particularly important because cases have been misdiagnosed as Kawasaki disease and appropriate control measures have not been taken promptly. be prominent in the acute phase of the illness and are the leading cause of long-term morbidity and mortality. In this phase the pericardium, myocardium, endocardium, and coronary arteries may all be involved. Pericardial effusion is detected by echocardiography in approximately 30% of patients with Kawasaki disease. It rarely progresses to tamponade and usually resolves spontaneously without specific therapy.
Clinically recognizable myocarditis is common. Signs include tachycardia out of proportion to the degree of fever. A gallop rhythm may be heard. The electrocardiogram is abnormal in one third of children with Kawasaki disease, showing decreased R wave voltage, ST segment depression, and T wave flattening or inversion. Myocardial inflammation may cause slowed conduction, resulting in prolonged PR or QT intervals or both. Local areas of ischemia may occur and predispose to atrial or, more commonly, ventricular arrhythmias. Congestive cardiac failure can also occur.
Coronary arterial abnormalities develop in approximately 20% of children with untreated Kawasaki disease and are the most common cause of both short-and long-term morbidity and mortality. Aneurysms have been detected within 3 days of onset of illness but more commonly occur from 10 days to 4 weeks after the onset of symptoms. The appearance of aneurysms more than 6 weeks after the onset of illness is uncommon. Factors associated with an increased risk of developing coronary arterial aneurysms include male gender; age less than 1 year; other signs or symptoms of pericardial, myocardial, or endocardial involvement, including arrhythmias; prolonged period of inflammation, including fever for more than 10 days; and recurrence of fever after an afebrile period of at least 24 hours.
Abnormalities of the coronary arteries include ectasia (coronary size larger than normal for age, [normal coronary artery size ranges from 1-2 mm in newborns and infants to 4.5-5.0 mm in teenagers8'9], or aneurysms that may be fusiform or saccular (near-equal axial and lateral diameters). Patients with giant aneurysms (internal diameter of at least 8 mm) have the worst prognosis and are at the greatest risk of developing coronary thrombosis, stenosis, or myocardial infarction. Giant aneurysms generally do not resolve. Coronary abnormalities are usually detected by high-resolution cardiac ultrasound. Angiography is sometimes used for diagno-sis, particularly in patients with suspected or definite echocardiographic changes or ischemia. Expertise is needed for a complete coronary artery evaluation and usually requires a qualified pediatric cardiologist because of considerable normal variations in the coronary arteries.
Myocardial infarction is the principal cause of death in Kawasaki disease. It may occur during the acute illness but happens more commonly within a year and may occur even later in patients who have giant aneurysms. Symptoms of myocardial infarction include unconsolable crying, vomiting, dyspnea, cardiovascular collapse, and shock. Chest pain has been described by children who can communicate the symptom. The majority of documented cases of infarction occur during sleep or while at rest. 10 Mortality from infarction has been reported to be approximately 25%. 10 In patients with coronary arterial abnormalities, aneurysms of other medium-sized muscular arteries, including the renal, brachial, and femoral arteries, can occur during the acute phase of the illness but more commonly are detected more than a year after the acute illness. Children with giant coronary aneurysms more likely have other arterial involvement.
Valvar involvement, primarily mitral regurgitation, has been described in about 1% of children with Kawasaki disease."1 Very rarely, regurgitation is severe enough to require valve replacement.12 '13 Noncardiac Findings. Multiple noncardiac clinical findings may be observed in patients with Kawasaki disease. Arthritis or arthralgia can occur in the first week of the illness and is usually polyarticular, involving the knees, ankles, and hands. Commonly a pauciarticular arthritis involving the knees, ankles, or hips appears during the second or third week of illness. Arthritis is more common in older girls.
Infants with Kawasaki disease are often more irritable than infants with other febrile illnesses. Signs and symptoms suggestive of aseptic meningitis may be present in some patients. A mononuclear pleocytosis in the cerebrospinal fluid is found in at least one fourth of the patients who undergo lumbar puncture.
Diarrhea, vomiting, and abdominal pain are common features. Mild to moderate elevations of serum transaminases with mild obstructive jaundice are occasionally noted. Acute acalculous distention of the gallbladder (hydrops) commonly occurs during the first 2 weeks of illness and can be identified by abdominal ultrasound.
Preceding or concurrent respiratory symptoms such as cough, rhinorrhea, otitis media, or pulmonary infiltrates are often observed.
Other less common findings include erythema and induration at the site of a recent vaccination with Bacille Calmette-Guerin (BCG). Auditory abnormalities, testicular swelling, and peripheral gangrene have also been reported.
Laboratory Findings. During the acute phase of the illness, patients with Kawasaki disease typically have neutrophilia, often including immature forms, increased acute phase reactants, mild anemia, hypoalbuminemia, and elevated serum immunoglobulin E levels. Thrombocytosis is frequently seen after the first week of the illness and may be marked. Proteinuria, probably secondary to fever, and sterile pyuria, probably a reflection of urethral involvement, are common. Some patients who do not fulfill the criteria outlined in Table 1 have been diagnosed subsequently as having "atypical" or "incomplete" Kawasaki disease. Patients with fever and fewer than four principal clinical findings can be diagnosed as having Kawasaki disease when coronary artery disease is detected. Some children with prolonged unexplained febrile illnesses, especially when associated with subsequent peripheral desquamation, may indeed have had atypical Kawasaki disease and should be reevaluated carefully for possible development of coronary artery disease.
Therapy During Acute Stage Initial therapy for Kawasaki disease is currently directed at reducing inflammation, particularly in the coronary arterial wall and myocardium. Later, therapy is directed toward preventing coronary thrombosis by inhibiting platelet aggregation. Specific therapy awaits discovery of the etiologic agent.
When possible, patients with Kawasaki disease should be treated within the first 10 days of onset of illness with intravenous gamma globulin and high-dose aspirin ( Table 3 ). The beneficial effect of intravenous gamma globulin on coronary abnormalities was first reported in Japan.14 A multicenter randomized controlled trial in the United States demonstrated that defervescence and resolution of inflammation were more pronounced and coronary arterial abnormalities were significantly less frequent in patients treated with intravenous gamma globulin plus aspirin than in patients treated with aspirin alone.15 A subsequent US trial compared a single 2 g/kg dose of intravenous gamma globulin to the dosage of 400 mg/kg per day for 4 days; both groups also received 100 mg/kg of aspirin per day. Children treated with the single-infusion regimen had significantly fewer coronary arterial abnormalities 2 weeks after enrollment than children treated with the 4-day infusion. By the seventh week after enrollment, the difference between the two groups was not significant. Children treated with the single-infusion regimen also had a more rapid defervescence and return of acute phase reactants to normal.16 Intravenous gamma globulin has been reported to reduce the likeli-rysms17 and appears to have a direct beneficial effect on abnormalities in cardiac function associated with the acute phase of Kawasaki disease. 18 High-dose aspirin alone hastens the resolution of acute manifestations of Kawasaki disease, particularly fever. The combination of aspirin at 80-100 mg/kg per day and intravenous gamma globulin has a more rapid anti-inflammatory effect than aspirin alone and appears to decrease the rate of development of coronary abnormalities. In children with Kawasaki disease, absorption of aspirin may be impaired and monitoring serum concentrations can be helpful in apparent nonresponders or in certain other circumstances.
After the child has become afebrile, aspirin should be reduced to 3-5 mg/kg given as a single daily dose for its antithrombotic effect. Low-dose aspirin is continued for approximately [6] [7] [8] weeks and then discontinued if no coronary arterial abnormalities have been detected by echocardiography. To reduce the risk of Reye's syndrome, aspirin therapy should be interrupted if the patient develops varicella or influenza, although the magnitude of such a risk is unknown. The use of dipyridamole to alter platelet activity should be considered during this interval if the patient is at high risk for myocardial infarction, that is, has developed significant coronary arterial abnormalities. If coronary arterial abnormalities are detected, lowdose aspirin therapy should be continued indefinitely and the patient referred to a pediatric cardiologist for longterm follow-up. Some Japanese and American investigators have attempted to target intravenous gamma globulin therapy only to those patients thought to be at highest risk of developing coronary arterial abnormalities by constructing risk scoring systems. None of these scoring systems is sensitive or specific enough to enable early prediction of which patients will develop coronary abnormalities. Therefore, the current recommendation is that all children diagnosed with Kawasaki disease within 10 days of onset of fever should receive intravenous gamma globulin and high-dose aspirin as early as possible.
Administration of parenteral live virus vaccines (measles, mumps, and rubella) should be delayed for at least 5 months after intravenous gamma globulin treatment because passively acquired antibodies may interfere with effective immunization.19 During a measles outbreak, however, it may be prudent to administer measles vaccine earlier to a previously unimmunized child and repeat the vaccination at a later time. Schedules for administration of other routine childhood vaccinations should not be interrupted. To reduce the risk of Reye's syndrome in patients on long-term aspirin therapy, administration of influenza vaccine is recommended.
Unresolved therapeutic issues. The mechanism of action of intravenous gamma globulin in Kawasaki disease is unknown. Gamma globulin may act by blockade or modulation of Fc receptors, by providing a specific antibody against an etiologic agent or toxin, by an anti-idiotypic mechanism resulting in suppression of antibody function, synthesis, or both, or by downregulation of cytokine production.
Because the mechanism of action of intravenous gamma globulin is unknown, standardization of intravenous gamma globulin preparations is not possible. It is unclear whether all commercially available intravenous hood of development of giant coronary artery aneu-gamma globulin preparations or various lots of the same preparation are equally effective.
The optimal dose of intravenous gamma globulin for treatment of acute Kawasaki disease remains undetermined. Two US studies using a single dose of 1 g/kg intravenous gamma globulin have been reported. One study was uncontrolled,20 and the other comparing doses of 1 g/kg to 400 mg/kg per day for 4 days involved a small number of patients.21 No trials comparing single doses of 1 g/kg and 2 g/kg have been reported.
Intravenous gamma globulin therapy should be considered for patients in whom the diagnosis of Kawasaki disease is made after the tenth day of illness if they have signs of ongoing inflammation or evolving coronary artery disease. Prolonged fever is associated with increased risk of coronary arterial abnormalities, including giant aneurysms. However, there are no available data from controlled studies on the benefit of intravenous gamma globulin in this circumstance. Some patients who present within 10 days of onset of illness already have coronary arterial abnormalities. These patients should receive aspirin and intravenous gamma globulin, although there are no data available on the acute or long-term benefits of such therapy.
Intravenous gamma globulin therapy may not always result in a prompt anti-inflammatory response. Some patients have persistent fever 24 hours after completion of the infusion. Other patients have an initial defervescence for at least 24 hours and then a recurrence of the fever. In both circumstances, retreatment with intravenous gamma globulin should be considered, although the benefit of retreatment to decrease the risk of coronary arterial sequelae has not been determined.
Treatment of atypical or incomplete Kawasaki disease with intravenous gamma globulin is based on clinical judgment. To identify such patients with certainty will not be possible until the etiology of the illness is discovered and a specific diagnostic test developed. Infants, particularly those under 6 months of age, frequently lack full diagnostic criteria for Kawasaki disease, and a high index of suspicion is necessary to make the diagnosis in these patients. Because these young infants are at an extremely high risk of developing coronary arterial abnormalities, early diagnosis and institution of appropriate therapy is particularly important. Overuse of intravenous gamma globulin should be discouraged because this treatment is expensive and has potential side-effects. When possible, patients with questionable diagnoses should be referred to a pediatric facility with established expertise in the diagnosis and management of Kawasaki disease before therapy is initiated.
